KR101498179B1 - Manufacturing method for Yongdamsagantanggagambang For the treatment of hyperlipidemia, Yongdamsagantanggagambang For the treatment of hyperlipidemia and composition produced by the same - Google Patents

Abstract

The present invention relates to a manufacturing method of Yongdamsagantanggagambang for treatment of hyperlipidemia. The Yongdamsagantanggagambang for treatment of hyperlipidemia comprises 18g of Coicis Semen, 15g of Rehmanniae Radix Crudus, 15g of Artemisiae Capillaris Herba, 15g of Scutellariae Radix, 10g of Glycyrrhizae Radix et Rhizoma, 10g of Cassiae Semen, 10g of Angelicae Gigantis Radix, 10g of Akebiae Caulis, 10g of Crataegi Fructus, 10g of Bupleuri Radix, 10g of Plantaginis Semen, 10g of Gardeniae Fructus, 10g of Alismatis Rhizoma, 6g of Gentianae scabrae Radix, 5g of Polygoni Multiflori Radix, and 3g of Chrysanthemi Flos with respect to a total weight of 167 g per pack. The manufacturing method of the Yongdamsagantanggagambang for treatment of hyperlipidemia comprises the steps of putting two packs of Yongdamsagantanggagambang herbs into 1000 ml of 80% alcohol and performing a reflux extraction process for 3 hours to obtain filtrate; vacuum concentrating the filtrate in a rotary vacuum evaporator to obtain a concentrated solution; freeze drying the concentrated solution by a freeze dryer to obtain 26.40 g of powder; and storing the powder in a freezer, wherein the powder is diluted with tertiary distilled water at a predetermined concentration and used. Accordingly, the present invention provides an effect of alleviating hyperlipidemia. In addition, the present invention provides effects of reducing impacts on liver function and enhancing antioxidant efficacy, and also provides a positive effect with respect to body weight and organ weight related to hyperlipidemia.

Description

Technical Field [0001] The present invention relates to a method for manufacturing hyperlipidemia, and a method of manufacturing hyperlipidemia for treating hyperlipidemia. [0001] The present invention relates to a method for manufacturing hyperlipidemia,

More particularly, the present invention relates to a method for manufacturing hyperglycemia for the treatment of hyperlipidemia, and a method for the manufacture of the hyperglycemic agent for the treatment of hyperlipidemia, The present invention relates to a tanggang composition for treating hyperlipidemia.

In general, obesity refers to a state of excessive accumulation of body fat, which is a complex syndrome caused by various causes such as genetic, nutritional, environmental, and social factors.

In other words, when the calorie intake exceeds the energy consumption, the remaining energy is converted to fat and stored in the fat cells, resulting in obesity.

In particular, it is divided into abdominal obesity (upper body obesity, central obesity) and lower body obesity (peripheral obesity) according to the distribution pattern of the body fat. In contrast to lower body obesity, diabetes, hypertension, hyperlipidemia, atherosclerotic cardiovascular disease , Ischemic heart disease).

Abdominal obesity is mainly used for exercise or diet therapy, but it is not effective in taking the obesity treatment drugs, such as suppression of fat absorption, the action of cerebral appetite center by controlling the secretion of hormones related to the regulation of food intake So that obesity was treated.

However, in the case of such a therapeutic agent for obesity, it is difficult for the general public to easily purchase and take it, and in particular, there have been various problems such as occurrence of other side effects in long-term administration.

[Related Technical Literature]

1. Saengmaeksan extract and saengmaeksan bean curd using saengmaeksan extract (Patent Application No. 10-2007-0043556)

2. Course Food for Improvement of Hyperlipidemia (Patent Application No. 10-2010-0116695)

Disclosure of Invention Technical Problem [8] The present invention is to solve the above-mentioned problems and to provide a method for producing hyperglycemia for relieving hyperlipemia.

In addition, the present invention provides a method for manufacturing hyperglycemia, Tanggang cyanide for treatment of hyperlipidemia, which has little effect on liver function and improves antioxidant efficacy.

The present invention also provides a method for manufacturing a Yongdam Sanggang tanggang cage for treating hyperlipidemia to provide a positive effect on weight and organ weight associated with hyperlipidemia.

However, the objects of the present invention are not limited to the above-mentioned objects, and other objects not mentioned can be clearly understood by those skilled in the art from the following description.

In order to accomplish the above object, in order to manufacture 167 g of the tanggaricum for the treatment of hyperlipidemia according to an embodiment of the present invention, 18 g of Uijin, 15 g of raw persimmon, 15 g of Injin蔯) 15g, gold (黄 15) 15g, licorice (甘 草) 10g, the killer 10g, the ginseng 10g, gongguk 10g, the mountain 10g, 10 grams of tea, 10 grams of tea ceremony, 10 grams of gardenia, 10 grams of Taesa, 10 grams of dragon grass, 5 grams of Hsuchuo and 3 grams of 甘 菊, And 2 layers of Yongdam Sanggang tanggang cages were placed in 1,000 ml of 80% alcohol and refluxed for 3 hours. The filtrate was concentrated under reduced pressure on a rotary vacuum evaporator, and the concentrated solution was lyophilized with a freeze dryer to obtain 26.40 g of powder , And the obtained powder is stored in a freezer and diluted with tertiary distilled water at a preset concentration.

delete

delete

delete

delete

The method for producing hyperglycemia according to an embodiment of the present invention provides an effect of alleviating hyperlipemia.

In addition, according to another embodiment of the present invention, the method for preparing Tanggu junk for the treatment of hyperlipidemia has little effect on liver function and provides an effect of improving the antioxidant efficacy.

In addition, according to another embodiment of the present invention, the method of manufacturing the Tanggu junk for the treatment of hyperlipidemia has a positive effect on weight and organ weight associated with hyperlipidemia.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, a detailed description of preferred embodiments of the present invention will be given with reference to the accompanying drawings. In the following description of the present invention, detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear.

The medicament for the treatment of hyperlipidemia, which is manufactured by the method of the present invention for the treatment of hyperlipidemia,

On the other hand, RAW 264.7 cells, animals and feeds, reagents, and equipment are used to test the effects on the Yongdam Sanggang tanggang cage for the treatment of hyperlipidemia produced by Yongdam Sanggang Tanggang cage manufacturing method for treating hyperlipidemia.

First, medicines among the constituents for Yongdam Sanggang Tanggang for the treatment of hyperlipidemia are shown in [Table 1].

Herbal medicine name Pharmacognostic name Weight (g) Uiin Coicis Semen 18 生 志 Huang (生地黄) Rehmanniae Radix Crudus 15 Injin Artemisiae Capillaris Herba 15 Golden (黄 芩) Scutellariae Radix 15 Licorice Glycyrrhizae Radix et Rhizoma 10 Acknowledgment Cassiae Semen 10 Angelica Angelicae Gigantis Radix 10 Wooden box Akebiae Caulis 10 Sansa Crataegi Fructus 10 Shiho Bupleuri Radix 10 Car electronics Plantaginis Semen 10 The gardener (梔 子) Gardeniae Fructus 10 Ta-sa (澤 泻) Alismatis Rhizoma 10 Yongdamcho Gentianae scabrae Radix 6 Hashuo Polygoni Multiflora Radix 5 Chanko (甘 菊) Chrysanthemi Flos 3 Total amount 167

That is, the composition and amount of the medicaments for the treatment of hyperlipidemia according to the present invention are as shown in Table 1 on the basis of one tablet.

<Cells for efficacy studies on Tanggang cells for the treatment of hyperlipidemia Yongdam Sagan>

Yongdam Sanggang Cells for the effect of Tanggang cell division are RAW 264.7 cells and purchased from Korea Cell Line Bank (Korea).

<Animal and Fodder for Efficacy Test on Yongdam Sanggang Tanggang Cage for Treating Hyperlipidemia>

CY7BL / 6J (6 weeks old, male, 18 ~ 22g) is used for the effect test on Jongam Sanggang tanggang. The experimental animals were fertilized with a 2 - week stabilization period and free diet was given to all experimental groups during the stabilization period. After the ballast was completed, water was supplied to the normal diet and the control group to induce hyperlipidemia, and the high cholesterol diet was free diet for 2 weeks. The conditions of the animal room were 22 ± 2 ℃ for conventional system, 200-300 Lux for 12 hours in a day, and all lights were blocked for 12 hours. This experiment was conducted in accordance with the animal ethics code of the Daejeon National Animal Experimental Ethics Committee (Animal Use Ethics Committee Approval No. DJUARB 2013-014). The content and the amount of the composition per kg of general diets and high cholesterol feeds are shown in [Table 2] and [Table 3] below.

Components Percentage (%) Crude protein 20.0 Crude fat 4.5 Crude fiber 6.0 Crude calcium oxide 7.0 Calcium 0.5 Phosphorus 1.0 Total amount 39.0

Components Weight (gm) Casein, 80 Mesh 200 L-Cystine 3 Maltodextrin 10 125 Sucrose 68.8 Cellulose, BW200 50 Soybean Oil 25 Lard 245 Mineral Mix S10026 10 DiCalcium Phosphate 13 Calcium Carbonate 5.5 Potassium Citrate, 1 H20 16.5 Vitamin Mix V10001 10 Choline Bitartrate 2 FD & C Blue Dye # 1 0.05 Total amount 773.85

<Experimental Method for the Treatment of Hyperlipidemia in Yongdam Sanggang Tanggang>

In the preparation of the test solution, 2 tablets of Tanggam cells were placed in 1,000 ml of 80% alcohol, and the mixture was refluxed for 3 hours. The filtrate was concentrated under reduced pressure on a rotary vacuum evaporator. The concentrated solution was lyophilized with a freeze dryer to obtain 26.40 g of powder. The obtained powder was stored in the freezer and diluted with the third distilled water to the required concentration.

<Experimental Results>

1. Stability check

1) Heavy metal content

The contents of heavy metals in the extracts of Canggu, Sanggang, Tangga, and Canggu were detected to be below the reference value for cadmium and not for the remaining heavy metals.

2) Analysis of HPLC pattern

As a result of pattern analysis using HPLC, the peaks of retention time at 210 nm were found at 26.21 min, 56.48 min and 56.74 min.

3) Effect on liver function

(1) Aspartate aminotransferase (AST)

AST in serum was found to be 65.4 ± 4.7 U / L in the normal group, 153.0 ± 8.2 U / L in the control group, and 111.8 ± 6.4 U / L in the Yongdam Sanggang Tangga cell group, Respectively.

(2) alanine aminotransferase (ALT)

Serum ALT was measured as 31.7 ± 1.7 U / L in the normal group, 47.6 ± 4.7 U / L in the control group, and 41.3 ± 2.4 U / L in the Yongdam Sanggang Tangga cell group.

(3) Alkaline phosphatase (ALP)

Serum ALP levels were 93.8 ± 6.7 U / L in the normal group, 180.4 ± 8.9 U / L in the control group, and 141.6 ± 10.4 U / L in the Yongdam Sanggang Tangga cell group, which was significantly lower than the control group Respectively.

4) Influence on new function

(1) Creatinine (Cr)

Serum creatinine levels were 0.53 ± 0.02 ㎎ / ㎗ in the normal group, 0.62 ± 0.02 ㎎ / ㎗ in the control group, and 0.56 ± 0.02 ㎎ / ㎗ in the Yongdam Sanggang Tangga cell group. And 9.7% in the Tangga cell group.

(2) Blood urea nitrogen (BUN)

Serum BUN concentration was found to be 14.43 ± 1.59 ㎎ / ㎗ in the normal group, 21.75 ± 2.82 ㎎ / ㎗ in the control group and 19.75 ± 2.77 ㎎ / ㎗ in the Jongam Sanggang Tangga cell group, And decreased by 9.2% in the Tanggar group.

2. In vitro

1) Effect on antioxidant efficacy

(1) Effect on DPPH radical scavenging ability

The DPPH elimination rate of Yongdam Sanggang tanggu cell extract was 1.6 ± 0.5% at the concentration of 1 ㎍ / ㎖, 6.7 ± 1.9% at the concentration of 10 ㎍ / ㎖, 66.9 ± 1.0% at the concentration of 100 ㎍ / ㎖, 94.8 ± 0.5%, indicating that the radical scavenging ability increases in a concentration-dependent manner.

(2) Effect on ABTS radical scavenging ability

The ABTS scavenging activity of Yongdam Sanggang tanggu cell extract was 2.3 ± 0.8% at the concentration of 1 ㎍ / ㎖, 3.0 ± 0.7% at the concentration of 10 ㎍ / ㎖, 17.6 ± 5.4% at the concentration of 100 ㎍ / ㎖, 92.7 ± 1.3%, indicating that the radical scavenging ability increases in a concentration dependent manner.

(3) Effect on production of ROS

The inhibitory activities of Rangsiae janggangganggangganggang extracts were 51.6 ± 15.8% in normal group and 94.9 ± 9.5% in 10 ㎍ / ㎖ of 1 ㎍ / ㎖, respectively, when the control group was 100.2 ± 0.2% ㎖, and 102.6 ± 10.7% at the concentration of 100 ㎍ / ㎖, respectively.

2) Effect on anti-inflammatory efficacy

(1) Effect on the production of nitric oxide (NO)

In the RAW 264.7 cell line, the NO production of the Yongdam Sanggang tanggu cell extract was 39.7 ± 4.1% in the control group and 100.8 ± 8.0% in the control group, 92.8 ± 8.0% and 10 ㎍ in the 1 ㎍ / / ㎖, 92.3 ± 7.2% and 57.3 ± 7.3% at 100 ㎍ / ㎖ concentration, respectively. There was a significant decrease at 100 ㎍ / ㎖ concentration compared to the control.

3. In vivo analysis

1) Effect on weight change

The effect on the body weight gain of hyperlipemia-induced rats was measured as 24.81 ± 0.68 g in the normal group, 26.48 ± 0.53 g in the control group, and 25.29 ± 0.62 g in the Yongdam Sanggang Tanggarh group. Compared to body weight.

2) Influence on organ weight

As a result of measuring the effects on the liver weight of hyperlipemic rats, 1.19 ± 0.07 g in the normal group, 1.57 ± 0.18 g in the control group and 1.41 ± 0.09 g in the Yongdam Sanggang Tanggarh group And decreased by 10.2% in the group treated with Yongdam Sanggang Tangga.

3) Effect on blood cholesterol

(1) Effect on change of total cholesterol

Serum total cholesterol level was measured as 85.99 ± 9.54 ㎎ / ㎗ in the normal group, 383.95 ± 35.96 ㎎ / ㎗ in the control group and 207.63 ± 13.03 ㎎ / ㎗ in the Yongdam - Respectively.

(2) High-density lipoprotein (HDL) cholesterol content

Serum HDL - cholesterol levels were found to be 40.00 ± 2.83 ㎎ / ㎗ in the normal group, 27.25 ± 2.44 ㎎ / ㎗ in the control group and 32.00 ± 2.55 ㎎ / ㎗ in the Yongdam - Respectively.

(3) Low-density lipoprotein (LDL) cholesterol content

Serum LDL cholesterol levels were 32.71 ± 7.70 ㎎ / ㎗ in the normal group, 219.38 ± 16.12 ㎎ / ㎗ in the control group and 142.75 ± 14.1 ㎎ / ㎗ in the Yongdam - Respectively.

4) Effect on Triglyceride Changes

Serum triglyceride content was 94.71 ± 6.10 ㎎ / ㎗ in normal group, 240.95 ± 14.46 ㎎ / ㎗ in control group and 183.60 ± 13.21 ㎎ / ㎗ in Yongdam - Sanggang Tangga cell group, which showed a significant decrease compared to the control group .

5) Effect on Glucose Change

Serum Glucose content was 64.60 ± 4.22 ㎎ / ㎗ in the normal group, 180.44 ± 13.14 ㎎ / ㎗ in the control group and 129.14 ± 10.77 ㎎ / ㎗ in the Yongdam Sanggang Tangga cell group, and significantly decreased compared to the control group .

5) Effect on production of Uric acid

Serum uric acid content was found to be 0.26 ± 0.05 ㎎ / ㎗ in the normal group, 0.63 ± 0.08 ㎎ / ㎗ in the control group and 0.40 ± 0.05 ㎎ / ㎗ in the Yongdam - Respectively.

6) Observation of liver tissue staining

(1) Effect on cell morphology of liver tissue

H & E staining of liver tissues revealed that the nucleus of the liver is located at the center of the cell, the size of the cell is constant, and the Kupffer cell is uniformly distributed throughout the liver cells. In the control group, fat follicles were observed in the liver cells, indicating that the nucleus of the cells was pushed into the edge of the cytoplasm, and the number of Cooper cells was significantly decreased compared to the normal group. In the Yongam Sanggang Tangga cell group, the size of the cells was increased due to the fat follicles in the liver cells, but the fat follicle was less than the control group and the nucleus was located at the center.

(2) fibrosis in the liver

In order to confirm the fibrosis in the liver, Masson's Trichrome staining showed that the control group was stained blue around the blood vessels compared to the normal group and the severity of fibrosis was observed. On the other hand, Similar to the group, the nucleus of the cell was located at the center, and the cell size was fixed. The recovery rate was good with '+' in the normal group, '+++' in the control group, and '++' in the group treated with Yongdam Sanggang Tangga.

(3) ADRP expression pattern by immunohistochemistry analysis

Histological examination of ADRP expression in liver tissues revealed that ADRP was strongly expressed in the control group by 30-50%, and that it was recovered as much as normal group in the Yongam Sanggang Tangga cell group.

As described above, preferred embodiments of the present invention have been disclosed in the present specification and drawings, and although specific terms have been used, they have been used only in a general sense to easily describe the technical contents of the present invention and to facilitate understanding of the invention , And are not intended to limit the scope of the present invention. It is to be understood by those skilled in the art that other modifications based on the technical idea of the present invention are possible in addition to the embodiments disclosed herein.

Claims (5)

16g is produced on the basis of one compostion, 18g of 薏苡仁, 15g of raw persimmon, 15g of persimmon, 15g of gold, 10g of licorice, 10g of 甘 草, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams of Chinese medicine, 10 grams, 6 grams of dragon grass, 5 grams of cucumber, 3 grams of sweet chrysanthemum,
The filtrate was concentrated under reduced pressure on a rotary vacuum evaporator, and the concentrated solution was lyophilized with a freeze dryer to obtain 26.40 g of a powder. Then, The obtained powder is stored in a freezer and diluted with a third concentration of distilled water at a preset concentration.
delete delete delete delete